{"name":"Dutch Colorectal Cancer Group","slug":"dutch-colorectal-cancer-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"FOLFOX/ FOLFIRI with bevacizumab","genericName":"FOLFOX/ FOLFIRI with bevacizumab","slug":"folfox-folfiri-with-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"FOLFOX/ FOLFIRI with panitumumab","genericName":"FOLFOX/ FOLFIRI with panitumumab","slug":"folfox-folfiri-with-panitumumab","indication":"Metastatic colorectal cancer, KRAS wild-type","status":"phase_3"},{"name":"FOLFOXIRI with bevacizumab","genericName":"FOLFOXIRI with bevacizumab","slug":"folfoxiri-with-bevacizumab","indication":"Metastatic colorectal cancer (first-line treatment)","status":"phase_3"},{"name":"capecitabine-irinotecan","genericName":"capecitabine-irinotecan","slug":"capecitabine-irinotecan","indication":"Metastatic colorectal cancer","status":"phase_3"}]}],"pipeline":[{"name":"FOLFOX/ FOLFIRI with bevacizumab","genericName":"FOLFOX/ FOLFIRI with bevacizumab","slug":"folfox-folfiri-with-bevacizumab","phase":"phase_3","mechanism":"FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients.","indications":["Metastatic colorectal cancer","First-line treatment of advanced colorectal cancer"],"catalyst":""},{"name":"FOLFOX/ FOLFIRI with panitumumab","genericName":"FOLFOX/ FOLFIRI with panitumumab","slug":"folfox-folfiri-with-panitumumab","phase":"phase_3","mechanism":"This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy.","indications":["Metastatic colorectal cancer, KRAS wild-type"],"catalyst":""},{"name":"FOLFOXIRI with bevacizumab","genericName":"FOLFOXIRI with bevacizumab","slug":"folfoxiri-with-bevacizumab","phase":"phase_3","mechanism":"FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation.","indications":["Metastatic colorectal cancer (first-line treatment)"],"catalyst":""},{"name":"capecitabine-irinotecan","genericName":"capecitabine-irinotecan","slug":"capecitabine-irinotecan","phase":"phase_3","mechanism":"Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc1ZJa3pSNWd4dU5TOGRwemRwSnRObHZ2TjBzOXJhYWlSbHo3c3NKQnhUMzBZdE1WQUFsSkNaeVJFZ1BNeUF3dUtCRUZIcEFCeUxKMmZTOV9kbmViTGs0d19OWWFwX0dXZ1Fwd0tSVzQyY1ZoU0w5Y25DUHRpR0ZCTkRTMnNLU2QtLXAwMm9meW81bVhzdU5YWmJxSlR2ZjZhVzZDR21Pb0FFcHlHSGw0c0xtTzV6aW5kYjB3WVFZYzR5bVc0SUp2OHNoOF8weEpnSVExMlg2akotYkpoZG43cW9ud2Voa2pmOW0yWVpkc3N4V3lQVVVLdVB1V1RNM3FuRXNVbDVHY2ROLWtLTGdPOTd2VQ?oc=5","date":"2026-02-19","type":"trial","source":"businesswire.com","summary":"Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026 - businesswire.com","headline":"Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Confere","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5udXN2Ri1xUThIU3U5ZVh0WGFWcjVsaUFrQ29LMnNnT2J0Y1lrZFpYWUg2UjBxSE0wZTRBRGgtX2lZT0xqTE4yZHpKTUFNTzN2eldv?oc=5","date":"2025-09-29","type":"deal","source":"FirstWord Pharma","summary":"Genmab to acquire Merus in $8B bet on bispecific antibody - FirstWord Pharma","headline":"Genmab to acquire Merus in $8B bet on bispecific antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxONUhJT1ViclZzMFMzSklZZnJPM1Yzb0hTYXdscFUtenljQmM3TG52MU5yYktDMVNmclNZMHgyeXJwOWk5Rk1rVVh5bW5Lc3ZSbEJoc1BJVDJxeVdyZzRjSFhIaTExMVhWT2MyR3ZvUUN4aW92R1RpR2tCdDVEUmFUMTVQcm9EWndESWdtcUJzUk9CbTdDb19ndmtFUUF3blk?oc=5","date":"2025-09-29","type":"deal","source":"BioPharma Dive","summary":"Genmab to acquire closely watched cancer drug in $8B Merus buyout - BioPharma Dive","headline":"Genmab to acquire closely watched cancer drug in $8B Merus buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQQ1ZhbmJReVdocXFCNkJMaUxEbXZsVWZBSWNPX0pON3oxT0xFZmpEQzB5THQ2Zzl4U2ZyTFNtQWR5dGFSdzBTS2gwalp6Wk9xaFdWMHllY2J6VWN1ME5lMDRMejRiaTZRMmhCSFI5R0ZORGdwMmVWREdaMHBTdGV1aTI2SDlNUXkxNHN1ejFoUTd4Tmswc2xkbHZNSU4?oc=5","date":"2025-09-12","type":"pipeline","source":"DutchNews.nl","summary":"Breakthrough Dutch cancer treatment held back by drug firms: FD - DutchNews.nl","headline":"Breakthrough Dutch cancer treatment held back by drug firms: FD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOby0xYUhIRHJJNlhZRXAyb0dvQkR1dDhOeVhmSEx3emhtN0l4YmJsMUJwOWVlME83NF9zVTlyeDI1UXhUdkhDb3M2emhsSUV0NU9vX3VoWUZDei1fMzF2c1ZBakhxQnB4bm5CUWwwNlh6ZmJKUnhueC1JOF9JbmhSTmxURmdHcURpSk12UmVzZHF3YTE5VjZRSDgzLW5XVTV4OFpqRWEtTkpnT05WQjdCdDZ3?oc=5","date":"2025-03-18","type":"pipeline","source":"Reuters","summary":"Widely used drugs on US imports list from Europe - Reuters","headline":"Widely used drugs on US imports list from Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQUVpUNkZMWUdQZFlDY0pCNzI2b2ZOb0lHNHlsanBQZjYwTzFEYWFyS002Ukt5azRyb29NaEttZF84dW9rTDFQcVVUc0U0bWNQN3ZoS05pM2JFNkhoUEwtSDZ2ZGdCaGJpUW1mUEJWUzdFWlR5dGZEeklPVFA5bmh3ZDJfbjRnTndzblFlUEVCc2EyNFNy?oc=5","date":"2025-01-13","type":"pipeline","source":"Frontiers","summary":"Discussion on the optimization of personalized medication using information systems based on pharmacogenomics: an example using colorectal cancer - Frontiers","headline":"Discussion on the optimization of personalized medication using information systems based on pharmacogenomics: an exampl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5ZX0gzc2F4dzNEVUJwSkZyNGg1aTF2TzFfZ1JDYkdyemlSVktFZGZvVmNwSk9WMTVnTlNhQ0lkMDhadURRNHVBTEh5Y2JBeDJxSDR2d3FJTzhSSVRob240STdOaHZvT3VYRWJUSWZ3?oc=5","date":"2024-01-18","type":"pipeline","source":"KED Global","summary":"Celltrion to export three anticancer drugs to Europe - KED Global","headline":"Celltrion to export three anticancer drugs to Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNSGV1ak8wenJIcHBWRTZEbGctalhPRWRCUkhZa1ZReXlLLXNSd2pZcDE1Um85bDBlNUV4dVd3aXpSR0swaUFHSVdJLUZhRVJKQktwWlBQVTlDRXBuY0JqbG5CRjBNU0FrN2pFVFppRU5laS16b0R6ZTBIU3BBelh5Q2tLNTlfY1Azb1J0aE11SXpqRG91OHo5UlNLM3lIeUxZNzJJRS14X24xOXBnbnI4cnhoU0NBdTloc2Vnd3VoMlN6UWNGSzk4?oc=5","date":"2022-04-25","type":"pipeline","source":"Institute for Research in Biomedicine | IRB Barcelona","summary":"MCLA-158, the first clinical candidate screened in organoids targeting cancer stem cells of solid tumours - Institute for Research in Biomedicine | IRB Barcelona","headline":"MCLA-158, the first clinical candidate screened in organoids targeting cancer stem cells of solid tumours - Institute fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XcTdJUzNHOFpVN3V1VHdIQUdDMldBOGp3RGxaZi1odWp2RHFwRzlTX1lnOWM3Q0lsczloc203eF8ybXBEWUNQU1ZrX09la2FENG5nWnYwS2tHVU1zLXVv?oc=5","date":"2022-04-19","type":"trial","source":"nature.com","summary":"First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer - nature.com","headline":"First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final surviv","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE55SUFKQXB3eWpxSmNHUlk5VzhUaWl4M2NsTWdGRU81b3ZyWmJKXzlnbDVYTG9YSU1ySW40SG1SUTFsbUxRbnFwYS1Bdm1yV2hVYUM5Tw?oc=5","date":"2017-06-20","type":"pipeline","source":"nature.com","summary":"Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors | British Journal of Cancer - nature.com","headline":"Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}